TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Sarepta Therapeutics Price Target Maintained With a $152.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $152
Cantor Fitzgerald Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)
Sarepta Therapeutics Price Target Maintained With a $181.00/Share by RBC Capital
Sarepta Therapeutics Analyst Ratings
RBC Capital Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
Evercore ISI Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)